{"id":69029,"date":"2026-03-13T12:12:34","date_gmt":"2026-03-13T12:12:34","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=69029"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"ss-31-elamipretide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/ss-31-elamipretide\/","title":{"rendered":"SS-31 (Elamipretide)"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is SS-31 (Elamipretide)?<\/h3>\n

SS-31<\/strong> (also called Elamipretide<\/strong> of Bendavia<\/strong>) is a synthetic tetrapeptide that selectively binds cardiolipin<\/strong> on the inner mitochondrial membrane, stabilizing mitochondrial function under stress. Developed by the Szeto-Schiller lab and now in late-stage clinical development by Stealth BioTherapeutics with FDA orphan-drug designation for rare mitochondrial disease. Supplied in 5\u00a0mg to 50\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n736992-21-5<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nC32<\/sub>H49<\/sub>N9<\/sub>O5<\/sub><\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n639.80 Da<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nD-Arg-2\u2032,6\u2032-Dmt-Lys-Phe-NH2<\/sub> (Bendavia, MTP-131)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (of zoals geleverd)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatisch water (aanbevolen) of steriel water voor kortere gebruiksperioden<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is SS-31 (Elamipretide)?<\/h2>\n

SS-31<\/strong> is a synthetic cell-permeable tetrapeptide (D-Arg-2’6′-dimethyl-L-Tyr-L-Lys-L-Phe, also abbreviated Szeto-Schiller 31<\/strong>) developed by Hazel Szeto and Peter Schiller at Cornell’s Weill Medical College starting in the 1990s. It is also known by its pharmaceutical-development names Elamipretide<\/strong> en Bendavia<\/strong>, and is being developed clinically by Stealth BioTherapeutics<\/strong>.<\/p>\n

Unlike most research peptides that bind cell-surface receptors, SS-31 is a mitochondria-targeted agent<\/strong> that crosses cell and organelle membranes to reach the inner mitochondrial membrane, where it binds cardiolipin<\/strong> \u2014 a phospholipid unique to that location. This selective lipid binding underpins its mechanism of action and distinguishes SS-31 from virtually every other research peptide.<\/p>\n

Molecular weight approximately 640\u00a0Da. SS-31 has FDA orphan-drug designation<\/strong> for primary mitochondrial myopathy and has been the subject of multiple human clinical trials \u2014 placing it further along the clinical development pipeline than most research peptides. It is supplied here as a high-purity lyophilized powder uitsluitend voor laboratoriumonderzoek<\/strong> (Stealth’s clinical product is a separate regulated therapeutic). For deeper mechanism, Szeto lab research history, and clinical-trial context, see our SS-31 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Cardiolipin-Targeted Mitochondrial Stabilization<\/h2>\n

SS-31’s mechanism is unique among research peptides because its target is a phospholipid, not a receptor protein. Three interconnected effects define its pharmacology:<\/p>\n